PH
Phathom Pharmaceuticals, Inc.
PHAT · NASDAQ
$9.50 +5.67% (+$0.51)
1M +11.11%
Market Cap $732.2M
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$12.64
33.1% upside
Current Price
$9.5
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PHAT is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
57 /100
Fair P/S 3.05x
EV/FFO N/A
P/B N/A
Growth
-
N/A Rev. growth N/A
FCF growth N/A
Book val. growth N/A
Profitability
20 /100
Weak Net margin 41.34%
Op. margin 16.96%
FCF margin 15.32%
Quality
13 /100
Poor ROA 30.29%
Asset turnover 0.73x
ROIC 23.36%
Debt
41 /100
Moderate Int. coverage -0.56x
Current ratio 1.92x
Net debt/EBITDA N/A
Stability
49 /100
Moderate EPS volatility 41.69%
Profitable years 0
Beta 0.51x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PHAT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Steven L. Basta
Employees
371
Headquarters
Florham Park
Upcoming events
29 OCT
Earnings
Upcoming earnings report